Previous close | 285.10 |
Open | 249.95 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 249.95 - 284.55 |
52-week range | 200.20 - 284.55 |
Volume | |
Avg. volume | 53 |
Market cap | N/A |
Beta (5Y monthly) | 0.60 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen's (AMGN) Blincyto is now approved for the treatment of adult and pediatric patients one month and older with Philadelphia chromosome-negative B-ALL in the consolidation phase, regardless of MRD status.
The latest trading day saw Amgen (AMGN) settling at $298.50, representing a -0.86% change from its previous close.